This is a preview of subscription content, log in via an institution to check access.
Reference
Agirrezabal I, et al. Real-World Budget Impact of the Adoption of Insulin Glargine Biosimilars in Primary Care in England (2015-2018). Diabetes Care : 11 Jun 2020. Available from: URL: http://doi.org/10.2337/dc19-2395
Rights and permissions
About this article
Cite this article
Savings with insulin glargine biosimilars in England could be much higher. PharmacoEcon Outcomes News 856, 35 (2020). https://doi.org/10.1007/s40274-020-6935-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6935-x